Esophagus Cancers
Gastrointestinal Tract Tumors: A Current Multimodal Approach and Radiotherapy, NOVA Publications , ss.81-93, 2026
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2026
- Yayınevi: NOVA Publications
- Sayfa Sayıları: ss.81-93
- Anahtar Kelimeler: adenocarcinoma, chemotherapy, esophageal cancer, multimodal treatment approach, radiotherapy, squamous cell carcinoma, surgery
- Recep Tayyip Erdoğan Üniversitesi Adresli: Evet
Özet
Esophageal cancer primarily consists of squamous cell carcinoma and adenocarcinoma, each associated with distinct risk factors. Squamous cell carcinoma originates in the squamous cells and is often linked to risk factors such as smoking, heavy alcohol consumption, and certain dietary deficiencies. Adenocarcinoma arises from glandular cells, typically those associated with the lower esophagus or the gastroesophageal junction. This histologic type has been on the rise in several Western countries and is often associated with gastroesophageal reflux disease and Barrett’s esophagus, a condition that can develop as a result of chronic acid exposure. The multimodal treatment for this cancer includes a combination of surgery, radiotherapy, and chemotherapy, meticulously tailored to the individual patient’s condition and cancer stage. Neoadjuvant therapy, involving chemotherapy and sometimes radiotherapy before surgery, is employed to reduce tumor size and enhance the feasibility of surgical resection. Overall, early detection and treatment are crucial for improving outcomes, as esophageal cancer is often diagnosed at advanced stages when it is more difficult to treat. Awareness of risk factors and symptoms is vital for early intervention. Recent advancements have introduced targeted therapies and immunotherapies, further broadening treatment options based on tumor genetics and specific biomarkers. A multidisciplinary team approach is essential in developing personalized treatment plans, optimizing patient outcomes, and managing side effects effectively. Continuous research and clinical trials aim to refine these multimodal strategies, making significant strides in improving survival rates and quality of life for patients with esophageal cancer.